This article is a follow-up to an article in our March 2012 update concerning the decision of the Swedish Medical Products Agency, prohibiting Boehringer Ingelheim AB in September 2011 from advertising the prescription-based product Pradaxa to the public, in the form of a press release.
As the impacts of the EU Whistleblower Protection Directive are seen across Sweden, it is clear the need for businesses to have a mature whistleblowing system is still present.
Subject to any transitional arrangement that may be contained in a possible withdrawal agreement, the Brexit has in particular the following consequences.